Venetoclax + Tagraxofusp
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Trial Timeline
Dec 1, 2025 → Sep 30, 2031
NCT ID
NCT07007052About Venetoclax + Tagraxofusp
Venetoclax + Tagraxofusp is a phase 2 stage product being developed by AbbVie for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07007052. Target conditions include Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
What happened to similar drugs?
2 of 13 similar drugs in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) were approved
Approved (2) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07007052 | Phase 2 | Recruiting |
Competing Products
20 competing products in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)